Literature DB >> 27484217

The incidence and mortality of major cancers in China, 2012.

Wanqing Chen1, Rongshou Zheng2, Hongmei Zeng2, Siwei Zhang2.   

Abstract

BACKGROUND: The National Central Cancer Registry (NCCR) collected population-based cancer registration data in 2012 from local registries and estimated the cancer incidence and mortality in China.
METHODS: In the middle of 2015, 261 cancer registries submitted reports on new cancer cases and deaths occurred in 2012. Qualified data from 193 registries were used for analysis after evaluation. Crude rates, number of cases, and age-standardized rates stratified by area (urban/rural), sex, age group, and cancer type were calculated according to the national population in 2012.
RESULTS: The covered population were 198,060,406 from 193 qualified cancer registries (74 urban and 119 rural registries). The major indicators of quality control, percentage of cases morphologically verified (MV%), death certificate-only cases (DCO%), and the mortality to incidence (M/I) ratio, were 69.13%, 2.38%, and 0.62, respectively. It was estimated that there were 3,586,200 new cancer cases and 2,186,600 cancer deaths in 2012 in China with an incidence of 264.85/100,000 [age-standardized rate of incidence by the Chinese standard population (ASRIC) of 191.89/100,000] and a mortality of 161.49/100,000 [age-standardized rate of mortality by the Chinese standard population (ASRMC) of 112.34/100,000]. The ten most common cancer sites were the lung, stomach, liver, colorectum, esophagus, female breast, thyroid, cervix, brain, and pancreas, accounting for approximately 77.4% of all new cancer cases. The ten leading causes of cancer death were lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, female breast cancer, brain tumor, leukemia, and lymphoma, accounting for 84.5% of all cancer deaths.
CONCLUSIONS: Continuous cancer registry data provides basic information in cancer control programs. The cancer burden in China is gradually increasing, both in urban and rural areas, in males and females. Efficient cancer prevention and control, such as health education, tobacco control, and cancer screening, should be paid attention by the health sector and the whole society of China.

Entities:  

Keywords:  Cancer registry; China; Epidemiology; Incidence; Mortality

Mesh:

Year:  2016        PMID: 27484217      PMCID: PMC4971631          DOI: 10.1186/s40880-016-0137-8

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


The National Central Cancer Registry (NCCR) called for data in 2012 from all population-based cancer registries in China, and the datasets were used to update the annual estimation for new cancer cases and deaths in China after data evaluation and analysis. There were 261 cancer registries, located in 32 provinces, autonomous regions, or municipalities, submitted cancer data in 2012. All data were checked and evaluated according to the criteria of data quality from NCCR, and 193 registries’ data were qualified and accepted for this updated cancer statistics in China in 2012. Cancer registries collected information on new cancer cases from hospitals, community health centers, medical insurance agents, and the Vital Statistics System (for cases only identified by death certification). Registries obtained information on cancer deaths from the death surveillance system, which collects death information from hospitals and the Civil Administration Bureau with available cremation records. Population information was collected from local statistical bureau or household register department in local public security bureau. Proportion of morphological verification (MV%), percentage of cancer cases identified with death certification only (DCO%), mortality to incidence (M/I) ratio, percentage of uncertified cancer (UB%), and percentage of cancer with undefined or unknown primary site (secondary) (O&U%) were used to evaluate the completeness, validity, and reliability of cancer statistics. Pooled data were stratified by area (urban/rural), sex, age group, and cancer site. Cancer incident cases and deaths were estimated using age-specific rates, which were stratified by area (urban/rural), sex (male/female), and age (grouped by 0, 1–4, 5–9,…, 80–84, 85-year old and above). The Chinese population census in 2000 and the Segi’s population were used for age-standardized rates (ASR) of incidence/mortality. The national incidences and mortalities were estimated using stratified rates and modelled national population in 2012. All 193 cancer registries (74 urban and 119 rural registries) covered a total of 198,060,406 population (100,450,109 in urban areas and 97,610,297 in rural areas). The overall indicators MV%, DCO%, and M/I ratio were 69.13%, 2.38%, and 0.62, respectively. They were 70.63%, 2.63%, and 0.59 in urban registries, compared to 67.31%, 2.09%, and 0.65 in rural registries. The estimates of new cases and deaths were 3,586,200 and 2,186,600 in 2012, respectively. The crude cancer incidence in China was 264.85/100,000 (289.30/100,000 in males and 239.15/100,000 in females), and age-standardized rates of incidence by the Chinese standard population (ASRIC) and by the world standard population (ASRIW) were 191.89/100,000 and 187.83/100,000 with a cumulative rate (for the whole population of 0–74 years old) of 21.82%. The crude incidence and ASRIC were 277.17/100,000 and 195.56/100,000 in urban areas and were 251.20/100,000 and 187.10/100,000 in rural areas. Cancer incidence was relatively low before 40 years old, after then increased dramatically, and finally peaked after 80 years old and slightly decreased after 85 years old. The pattern was similar between urban and rural areas (Table 1).
Table 1

Cancer incidence in China in 2012

(This table has been published previously and is reproduced with permission from the Chinese Journal of Cancer Research, see Ref. [3])

AreasSexNew cases (×103)Crude incidence (1/105)ASRIC (1/105)ASRIW (1/105)Cumulative rate (%)a
All areasBoth3586.2264.85191.89187.8321.82
Male2007.6289.30216.17214.3325.39
Female1578.6239.15170.08163.8118.32
Urban areasBoth1973.0277.17195.56190.8821.91
Male1062.0292.31212.68210.6324.71
Female911.0261.39181.30174.0019.28
Rural areasBoth1613.2251.20187.10183.9121.67
Male945.6286.00220.03218.4226.14
Female667.6214.28156.14151.3517.14

ASRIC age-standardized rate of incidence by the China population in 2000, ASRIW age-standardized rate of incidence by the Segi’s population

a The cumulative rate of the whole population of 0–74 years old

Cancer incidence in China in 2012 (This table has been published previously and is reproduced with permission from the Chinese Journal of Cancer Research, see Ref. [3]) ASRIC age-standardized rate of incidence by the China population in 2000, ASRIW age-standardized rate of incidence by the Segi’s population a The cumulative rate of the whole population of 0–74 years old The crude cancer mortality in China was 161.49/100,000 (198.99/100,000 in males and 122.06/100,000 in females), age-standardized rates of mortality by the Chinese standard population (ASRMC) and by the world standard population (ASRMW) were 112.34/100,000 and 111.25/100,000, and the cumulative mortality (for the whole population of 0–74 years old) was 12.61%. The crude mortality and ASRMC were 159.00/100,000 and 107.23/100,000 in urban areas and were 164.24/100,000 and 118.22/100,000 in rural areas. The cancer mortality was relatively low before 45 years old and then dramatically increased, reaching the peak after 85 years old. The mortality in rural areas was highest in the age group of 80–84 years old. The age-specific mortality in males was lower in urban areas than in rural areas in most of age groups before 80 years old (Table 2).
Table 2

Cancer mortality in China in 2012

(This table has been published previously and is reproduced with permission from the Chinese Journal of Cancer Research, see Ref. [3])

AreasSexDeaths (×103)Crude mortality (1/105)ASRMC (1/105)ASRMW (1/105)Cumulative rate (%)a
All areasBoth2186.6161.49112.34111.2512.61
Male1380.9198.99146.51145.5716.57
Female805.7122.0680.0078.898.66
Urban areasBoth1131.8159.00107.23106.1311.70
Male706.2194.37138.60137.7415.30
Female425.7122.1477.7476.558.18
Rural areasBoth1054.8164.24118.22117.0613.63
Male674.7204.06155.46154.2817.99
Female380.1121.9882.6481.609.21

ASRMC age-standardized rate of mortality by the China population in 2000, ASRMW age-standardized rate of mortality by the Segi’s population

a The cumulative rate of the whole population of 0–74 years old

Cancer mortality in China in 2012 (This table has been published previously and is reproduced with permission from the Chinese Journal of Cancer Research, see Ref. [3]) ASRMC age-standardized rate of mortality by the China population in 2000, ASRMW age-standardized rate of mortality by the Segi’s population a The cumulative rate of the whole population of 0–74 years old Lung cancer was the most common cancer in all areas, followed by gastric, liver, colorectal, and esophageal cancers with estimated new cases of 704,800, 423,500, 366,100, 331,300, and 286,700, respectively. Lung cancer was the most frequently diagnosed cancers in males, followed by gastric, liver, esophageal, and colorectal cancers; breast cancer was the most common cancer in females, followed by lung, colorectal, gastric, and cervical cancers (Table 3; Figs. 1, 2). The ten most common cancers accounted for approximately 77.4% of all cancer cases in urban and rural areas. In urban areas, lung cancer was the most frequently diagnosed cancer, followed by colorectal, gastric, female breast, and liver cancers. Lung cancer had been becoming the most frequently diagnosed cancer (326,600 new cases with an incidence of 50.86/100,000), followed by gastric, esophageal, liver, and colorectal cancers.
Table 3

Top ten cancer incidences in China in 2012

(This table is modified from a previous publication with permission, see Ref. [3])

CNS central nervous system

Fig. 1

Cancer incidence and mortality in urban and rural areas for males in China in 2012 (1/100,000). CNS central nervous system

Fig. 2

Cancer incidence and mortality in urban and rural areas for females in China in 2012 (1/100,000). CNS central nervous system

Top ten cancer incidences in China in 2012 (This table is modified from a previous publication with permission, see Ref. [3]) CNS central nervous system Cancer incidence and mortality in urban and rural areas for males in China in 2012 (1/100,000). CNS central nervous system Cancer incidence and mortality in urban and rural areas for females in China in 2012 (1/100,000). CNS central nervous system Lung cancer was the first leading cause of cancer death in China, followed by liver, gastric, esophageal, and colorectal cancers with estimated deaths of 569,400, 321,200, 298,500, 210,900, and 159,300, respectively. In males, lung cancer was the leading cause of cancer death, followed by liver, gastric, esophageal, and colorectal cancers; whereas in females, lung cancer was still the leading cause of cancer death, followed by gastric, liver, colorectal, and esophageal cancers (Table 4; Figs. 1, 2). The top ten leading causes of cancer death accounted for approximately 84.5% of all cancer deaths. The cancer patterns showed difference between urban and rural areas and between males and females. The leading causes of cancer death in rural areas were lung, liver, gastric, esophageal, and colorectal cancers, whereas the leading causes of cancer death in urban areas was lung, liver, gastric, colorectal, and esophageal cancers.
Table 4

Top ten cancer mortalities in China in 2012

(This table is modified from a previous publication with permission, see Ref. [3])

CNS central nervous system

Top ten cancer mortalities in China in 2012 (This table is modified from a previous publication with permission, see Ref. [3]) CNS central nervous system Compared with the figures in 2011 [1] and 2010 [2], cancer burden kept increasing, mostly because of the population increase and aging. Timely report of cancer registry provides basic information for policymakers, researchers, and clinicians. With the registry data getting more accurate, it plays more important role in cancer control in China.
  3 in total

1.  National cancer incidence and mortality in China, 2012.

Authors:  Wanqing Chen; Rongshou Zheng; Tingting Zuo; Hongmei Zeng; Siwei Zhang; Jie He
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  The updated incidences and mortalities of major cancers in China, 2011.

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang
Journal:  Chin J Cancer       Date:  2015-09-14

3.  The incidences and mortalities of major cancers in China, 2010.

Authors:  Wan-Qing Chen; Rong-Shou Zheng; Si-Wei Zhang; Hong-Mei Zeng; Xiao-Nong Zou
Journal:  Chin J Cancer       Date:  2014-07-11
  3 in total
  87 in total

1.  Bilateral vs. unilateral endoscopic ultrasound-guided celiac plexus neurolysis for abdominal pain management in patients with pancreatic malignancy: a systematic review and meta-analysis.

Authors:  Fan Lu; Jifu Dong; Yuming Tang; He Huang; Hui Liu; Li Song; Kexian Zhang
Journal:  Support Care Cancer       Date:  2017-09-27       Impact factor: 3.603

Review 2.  Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition).

Authors:  Hui Li; Wentao Fang; Zhentao Yu; Yousheng Mao; Longqi Chen; Jie He; Tiehua Rong; Chun Chen; Haiquan Chen; Keneng Chen; Ming Du; Yongtao Han; Jian Hu; Jianhua Fu; Xiaobin Hou; Taiqian Gong; Yin Li; Junfeng Liu; Shuoyan Liu; Lijie Tan; Hui Tian; Qun Wang; Jiaqing Xiang; Meiqing Xu; Xin Ye; Bin You; Renquan Zhang; Yan Zhao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast cancer.

Authors:  Xuan Li; Danian Dai; Bo Chen; Hailin Tang; Xiaoming Xie; Weidong Wei
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

4.  Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer.

Authors:  Bibo Tan; Yong Li; Yan Di; Liqiao Fan; Qun Zhao; Qingwei Liu; Dong Wang; Nan Jia
Journal:  J Clin Lab Anal       Date:  2017-11-23       Impact factor: 2.352

5.  Risk of breast cancer and adipose tissue concentrations of polychlorinated biphenyls and organochlorine pesticides: a hospital-based case-control study in Chinese women.

Authors:  Wenlong Huang; Yuanfang He; Jiefeng Xiao; Yuanni Huang; Anna Li; Meirong He; Kusheng Wu
Journal:  Environ Sci Pollut Res Int       Date:  2019-09-07       Impact factor: 4.223

6.  Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer.

Authors:  Rong Yang; Ting-Ting Cai; Xiao-Jun Wu; Yi-Na Liu; Jia He; Xiao-Shi Zhang; Gang Ma; Jiang Li
Journal:  Immunology       Date:  2018-06-11       Impact factor: 7.397

7.  Three-year interval for endoscopic screening may reduce the mortality in patients with gastric cancer.

Authors:  Sang Il Choi; Boram Park; Jungnam Joo; Young-Il Kim; Jong Yeul Lee; Chan Gyoo Kim; Il Ju Choi; Myeong-Cherl Kook; Soo-Jeong Cho
Journal:  Surg Endosc       Date:  2018-07-13       Impact factor: 4.584

8.  FOXD4 induces tumor progression in colorectal cancer by regulation of the SNAI3/CDH1 axis.

Authors:  Cheng Chen; Maimaiti Aihemaiti; Xin Zhang; Hui Qu; Jie Jiao; Qilong Sun; Wenbin Yu
Journal:  Cancer Biol Ther       Date:  2018-09-25       Impact factor: 4.742

9.  Salvage lymphadenectomy for isolated cervical lymph node recurrence after curative resection of thoracic esophageal squamous cell carcinoma.

Authors:  Zhen Wang; Shaofeng Lin; Feng Wang; Shuoyan Liu
Journal:  Ann Transl Med       Date:  2019-06

10.  Long-term survival of the middle and lower thoracic esophageal cancer patients after surgical treatment through left or right thoracic approach.

Authors:  Ding Yang; You-Sheng Mao; Jie He; Shu-Geng Gao; Ke-Lin Sun; Ju-Wei Mu; Qi Xue; Da-Li Wang; Yu-Shun Gao; Jun Zhao; Xiang-Yang Liu; De-Kang Fang; Jian Li; Yong-Gang Wang; Liang-Ze Zhang; Jin-Feng Huang; Bing Wang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.